HIV prevention pill study aims to Fine-Tune protection for women
NCT ID NCT05140954
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective a daily HIV prevention pill (TAF-FTC) is in 54 Kenyan cisgender women. Participants took different numbers of doses each week to mimic real-world use. The goal was to measure drug levels in the blood and tissues, helping doctors better understand how well the pill works in women.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kenya Medical Research Institute - Partners in Health Research and Development
Thika, Kenya